Back to search

The University of Edinburgh

Surgery for inflammatory bowel disease in the era of advanced medical therapy

Abstract

dc:description.abstract

Ulcerative colitis (UC) and Crohn’s disease (CD) are the principal forms of inflammatory bowel disease (IBD). They are characterised by inflammation of the GI tract with significant heterogeneity in the location, extent and severity of inflammation both between and within sub-types of IBD. IBD prevalence is estimated to be rising, but no detailed, recent UK data was available. The last reported prevalence estimate in the UK was 0.40% in 2003. Treatment of IBD has classically involved the use of medical therapy to induce and maintain remission with surgery reserved for disease that is refractory to medical therapy or where irreversible complications have occurred. Treatment was historically limited to corticosteroids and immunomodulators such as thiopurines. The introduction of advanced therapies including monoclonal antibodies (biologic therapy) and small molecules directed at various targets in the inflammatory cascade has resulted in a paradigm shift in the management of IBD over the past two decades. Advanced therapy is effective in maintaining remission in ulcerative colitis, though the effect on colectomy rates remains unclear. In the UK, the use of anti-TNF and anti-α4β7 treatments for maintenance therapy in UC was completely restricted by NICE until 2015 with multiple agents now available for use in clinical practice. The use of biologic therapy for Crohn’s disease has been present for over two decades and continues to evolve with more agents available and greater understanding of their optimal use, the effect of this on the requirement for resectional bowel surgery and the impact on perianal disease remains unclear. The aim of chapter 2 was to establish the current, and project future, prevalence of IBD in Lothian, Scotland and to develop a population based cohort for analysis of temporal trends of surgery. The aim of chapter 3 was to describe the patterns of advanced therapy prescribing and colectomy rates over time for UC within our population based cohort. The aim of chapter 4 was to describe patterns of biologic prescription and resectional surgery for Crohn’s disease over time in our population-based cohort. The aim of Chapter 5 was to describe the incidence of perianal Crohn’s disease in the era of biologic therapy and trends in the rate of perianal surgery within our population based cohort. METHODS: An all-age multiparameter search strategy was performed using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997–2018), IBD pathology coding (1990–2018), primary and secondary care prescribing data (2009–2018) and a paediatric registry, (1997–2018) to identify ’possible’ IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per LennardJones/Porto criteria. All patients (adult and paediatric) with a diagnosis of UC who received maintenance biologic treatment and/or underwent a colectomy in Lothian, Scotland between 2005 to 2021 were identified by interrogating multiple clinical and administrative databases. Linear and segmental regression analyses were used to identify the annual percentage change (APC) and temporal trends (statistical joinpoints) in biologic prescription and colectomy rates. A retrospective cohort study of all patients diagnosed with CD in Lothian, Scotland between 1/1/2000 and 31/12/2017 was performed. Cumulative probability and hazard ratios for bowel surgery and biologic prescription from diagnosis were calculated and compared using the log-rank test and Cox regression analysis stratified by year of diagnosis into sub-cohorts. Time trend analysis was performed for the period 1/1/2000 to 31/12/17 by calculating cumulative incidence of perianal CD and biologic prescription in newly diagnosed Crohn’s disease, stratified by era of diagnosis (2000-2008 and 2009-2017). RESULTS: In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn’s disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture–recapture methods identified an additional 427 ’missed’ cases (95% CI 383 to 477) resulting in a ’true’ prevalence of 832/100 000 (95% CI 827 to 837). Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p<0.0001). Rates of maintenance biologic therapy initiation increased from 0.05 per 100 UC patients in 2005 to 1.26 in 2018 (p<0.001). Colectomy rates per 100 UC patients fell from 1.47 colectomies in 2005 to 0.44 in 2018 (p<0.001). The colectomy APC decreased by 4.1% per year between 2005 and 2014 and by 18.5% between 2014 and 2021. Temporal trend analysis (2005-2021) identified a significant joinpoint in colectomy rates in 2014 (p=0.019). The five year cumulative risk of resectional surgery for Crohn’s disease was 20.4% in Cohort 1 (2000 to 2004),18.3% in Cohort 2 (2005-2008), 14.7% in Cohort 3 (2009-2013) and 13.0% in Cohort 4 (2014-2017) (Log rank p<0.001). The five year cumulative risk of biologic prescription was 5.7% in Cohort 1, 12.2% Cohort 2, 22.0 in Cohort 3 and 44.9% in Cohort 4 (Log rank p<0.001). Rates of surgery for perianal CD fell from 5.1 to 2.0 operations per 100 CD patients per year between 2000 and 2017 (p<0.001) giving an annual percentage change of -3.4% (-4.9% to -1.9% 95% CI). 5 year risk of developing perianal CD was 12.8% (9.5-16.6%) with no significant difference identified when stratified by era of diagnosis (p=0.116). The cumulative incidence of biologic prescription was significantly higher in patients with peri-anal disease p<0.001. CONCLUSION: I report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide that could be linked to clinical and administrative databases for further interrogation and analysis. Maintenance biologic use for UC increased sharply following change in national guidance, this has been parallelled by a significant reduction in the rates of colectomy over the same time period. The increased and earlier use of biologic therapy in CD patients also corresponds with a decreasing requirement for surgery over time within our cohort. These data suggest that surgical rates are declining in line with increased and earlier use of biologics in Crohn’s disease. The incidence of perianal CD remains unchanged over time, with an overall decrease in the requirement for surgery and increased use of biologic medication in this subset of CD patients. Overall although we cannot ascribe causality it appears that more aggressive medical therapy could be associated with a reduction in surgery required for all subsets of IBD in our population. These results are striking and are directly relevant to clinical practice and the lives of patients with IBD.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Jenkinson, Philip
Advisors dc:contributor.advisor
  • Lees, Charlie
  • Ho, Gwo-Tzer
  • Watson, Angus

Subjects

dc:subject × 7

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Jenkinson, Philip. Surgery for inflammatory bowel disease in the era of advanced medical therapy. The University of Edinburgh, 2024. https://hdl.handle.net/1842/42708